ClinicalTrials.gg
TerminatedNCT00136916Updated Feb 18, 2010Results posted

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

A Phase 3 interventional study of Inhaled Insulin and Subcutaneous insulin in Diabetes Mellitus, sponsored by Pfizer. Terminated at 92 sites in 4 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-02-18.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
635
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing insulin in Diabetes Mellitus — 1 open to participants now, 2 under way, none of them phase 3. Insulin · Diabetes Mellitus.

Enrollment
6th of 49
635 · median 74
Started
2002
with 1 other
Phase 3
11 of 51
none open now
Registered
4th of 51
by date
Lead sponsor
5 of 51
Pfizer

Among the 51 studies testing insulin in Diabetes Mellitus, this one is the 6th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2002, is one of 11 in phase 3, and was the 4th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 51 studies testing insulin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, or all of them as a file.
02

Study summary

This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inhaled insulin is Exubera®.

This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.

Read the detailed description

Pfizer announced in October 2007 that it would stop marketing Exubera. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171029 was terminated on June 9, 2008. Neither safety nor efficacy reasons were the cause of the study termination.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus

Exclusion criteria

Exclusion Criteria:

  • Asthma
  • Smoking Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
635 participants (actual)

Study arms

  • Experimental
    Inhaled Insulin

    Inhalable short-acting insulin

    Drug: Inhaled Insulin

  • Active comparator
    Subcutaneous insulin

    Drug: Subcutaneous insulin

Interventions

  • Inhaled insulin with dose adjusted according to premeal blood glucose

    Also known as: Exubera

  • Subcutaneous insulin with dose adjusted according to premeal blood glucose

06

What researchers measure

Primary outcomes

  1. Change From Month 3 in Forced Expiratory Volume in 1 Second (FEV1)

    Change from Month 3: mean of (value of observed FEV1 \[forced expiratory volume in the first second of forced exhalation\] in liters \[L\] at treatment observation minus Month 3 value).

    Time frame: Month 3 through extension Month 60

  2. Change From Baseline in FEV1

    Change from baseline: mean of (value of observed FEV1 \[L\] at treatment observation minus baseline value).

    Time frame: Baseline through extension follow up Month 3

  3. Annual Rate of Change in FEV1

    Annual rate of change in FEV1 calculated as slope over time \[visit\] for forced expiratory volume in 1 second measured as liters per year (L/yr).

    Time frame: Week -2 through extension follow up Month 3 or end of study

  4. Summary of ≥ 15 % Decliners in FEV1

    Number of subjects with a post-baseline FEV1 decrease of ≥ 15 % \[(baseline observed value - visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrrent illness, a repeat FEV1 was performed.

    Time frame: Month 3 through extension follow up Month 3

  5. Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco)

    Annual rate of change in DLco calculated as slope over time (visit) measured as milliliters per minute per millimeters of mercury per year (ml/min/mmHg/yr).

    Time frame: Week -2 through extension follow up Month 3 or end of study

  6. Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)

    Change from baseline: mean of (value of observed DLco \[milliliters per minute per millimeters of mercury (ml/min/mmHg)\] at treatment observation minus baseline value).

    Time frame: Baseline through extension follow up Month 3

  7. Summary of ≥ 20 % Decliners in DLco

    Number of subjects with a post-baseline DLco decrease of ≥ 20 % \[(baseline observed value - visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrrent illness, a repeat DLco was performed.

    Time frame: Month 3 through extension follow up Month 3

Secondary outcomes

  1. Forced Vital Capacity (FVC)

    Forced Vital Capacity (FVC) measured in liters (L).

    Time frame: Week -3 through extension follow up Month 3 or end of study

  2. Total Lung Capacity (TLC)

    Total Lung Capacity measured in liters (L).

    Time frame: Baseline through extension follow up Month 3

  3. Change From Baseline in Glycosylated Hemoglobin (HbA1c)

    Change from baseline: mean of (value of observed HbA1c \[%\] at treatment observation minus baseline value).

    Time frame: Baseline through extension follow up Month 3

  4. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline: mean of (value of observed FPG \[milligrams per deciliter (mg/dL)\] at treatment observation minus baseline value).

    Time frame: Baseline through extension follow up Month 3

  5. Change From Baseline in Body Weight

    Change from baseline: mean of (value of observed body weight \[kilograms (kg)\] at treatment observation minus baseline value).

    Time frame: Baseline through extension follow up Month 3

  6. Total Daily Long-acting Insulin Dose (Unadjusted for Body Weight)

    Total daily long-acting insulin dose unadjusted for body weight. Long-acting (units) insulin for inhaled insulin and subcutaneous treatment groups included NPH insulin, Ultralente®, and insulin glargine.

    Time frame: Month 3 through extension Month 36

  7. Total Daily Long-acting Insulin (Adjusted for Body Weight)

    Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting (units) insulin for inhaled insulin and subcutaneous treatment groups included NPH insulin, Ultralente®, and insulin glargine.

    Time frame: Month 3 through extension Month 36

  8. Total Daily Short-acting Insulin Dose (Unadjusted for Body Weight)

    Total daily dose of short-acting insulin unadjusted for body weight. Short-acting insulin (milligrams \[mg\]) for the inhaled insulin treatment group was inhaled insulin; short-acting insulin (units) for the subcutaneous insulin treatment group included insulin lispro, insulin aspart, and regular insulin.

    Time frame: Month 3 through extension Month 36

  9. Total Daily Short-acting Insulin Dose (Adjusted for Body Weight)

    Total daily dose of short-acting insulin adjusted for body weight. Short-acting insulin (mg) for the inhaled insulin treatment group was inhaled insulin (mg divided by kg); short-acting insulin (units) for the subcutaneous insulin treatment group included insulin lispro, insulin aspart, and regular insulin (units divided by kg).

    Time frame: Month 3 through extension Month 36

  10. Lipid Panel: Total Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, and Triglycerides

    Lipid values for total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides measured as milligrams per deciliter (mg/dL).

    Time frame: Week -4 through Month 24

  11. Hypoglycemic Event Rates

    Hypoglycemic event rate; hypoglycemic event identified by characteristic symptoms of hypoglycemia with no blood glucose (BG) check with prompt resolution with food intake, SC glucagon, or intravenous (IV) glucose; characteristic symptoms with BG of 59 mg/dL (3.2 mmol/L) or less with or without symptoms. Crude event rate = total events divided by subject months (elapsed number of months a subject was in the study at each time interval).

    Time frame: Month 1 through extension Month 36

  12. Severe Hypoglycemic Event Rates

    Severe hypoglycemic event rate; all 3 criteria were met: subject unable to treat self, exhibited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty awakening, suspected seizure, loss of consciousness); BG measurement ≤49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, SC glucagon, or IV glucose. Crude event rate: total events divided by subject months multiplied by 100 (\[total events/subject months\]\*100). Subjects months: elapsed number of months subject was in study in each time interval.

    Time frame: Month 1 through extension Month 36

  13. Cough Questionnaire

    Clinician administered 6 question instrument to measure cough frequency (night, day), severity, timing in relation to short-acting insulin dosing, severity related to insulin dosing (SC or inhaled), and productivity of cough; range 0 (indicates no symptoms) to 4 (indicates severe symptoms). Questionnaire administered at Week 0 then if and only if, cough is identified as an adverse event not explained by a concomitant condition, such as an upper respiratory tract infection.

    Time frame: Week 0 and if indicated through extension follow up Month 3

  14. Baseline Dyspnea Index (BDI)

    Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI score range 0 (very severe impairment) to 4 (no impairment) scaled to a BDI focal score (0-12). Lower score indicates greater impairment.

    Time frame: Week -1

  15. Transition Dyspnea Index (TDI)

    Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI score range -3 (major deterioration) to +3 (major improvement); sum of all domains yields the TDI focal score (-9 to +9); lower score indicates greater deterioration. Compared to previous scoring to determine deterioration or improvement.

    Time frame: Week 4 through extension follow up Month 3 or end of study

  16. High Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Within Normal Limits

    Number of subjects with Yes or No responses (within normal limits at specified time points = Yes or not within normal limits at specified time points = No) at observation when HRCT of thorax was within normal limits at baseline.

    Time frame: Baseline, M12, M24, Ext M6, Ext M18, Ext M36

  17. High Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Not Within Normal Limits

    Number of subjects with Yes or No responses (within normal limits at specified time points = Yes or not within normal limits at specified time points = No) at observation when HRCT of thorax was not within normal limits at baseline. "No" response at observation further categorized as no significant change (NSC), more abnormal (\> Abn), or less abnormal (\< Abn).

    Time frame: Baseline, M12, M24, Ext M6, Ext M18, Ext M36

  18. Insulin Antibodies

    Observed values for insulin antibodies measured as micro units per milliliter (microU/mL).

    Time frame: Baseline through extension Month 36

07

Results

Posted Jan 18, 2010
Limitations and caveats
Due to early termination of study, none of the subjects completed the study as planned. Subjects active at the time of study termination completed an end-of-study assessment and a 3-month follow-up visit.

Participant flow

Participant flow — Overall Study
MilestoneInhaled Insulin (Exubera®)Subcutaneous Insulin
Started319316
Received treatment316311
Completed194212
Not completed125104
Withdrew: Never received study treatment35
Withdrew: Death13
Withdrew: Adverse event278
Withdrew: Laboratory abnormality01
Withdrew: Lack of efficacy133
Withdrew: Lost to follow-up1214
Withdrew: Withdrawal by subject4446
Withdrew: Other2224
Withdrew: Discontinued in follow up period30

Outcome measures

PrimaryChange From Month 3 in Forced Expiratory Volume in 1 Second (FEV1)

Change from Month 3: mean of (value of observed FEV1 \[forced expiratory volume in the first second of forced exhalation\] in liters \[L\] at treatment observation minus Month 3 value).

Time frame:
Month 3 through extension Month 60
Reported as:
Mean · L

No measurements were reported for this outcome.

PrimaryChange From Baseline in FEV1

Change from baseline: mean of (value of observed FEV1 \[L\] at treatment observation minus baseline value).

Time frame:
Baseline through extension follow up Month 3
Reported as:
Mean · L
Change From Baseline in FEV1
LInhaled Insulin (Exubera®)Subcutaneous Insulin
Baseline (n=311, 304)2.91 ± 0.682.93 ± 0.71
Month 3 (M3) (n=290, 291)-0.06 ± 0.13-0.01 ± 0.15
M6 (n=281, 280)-0.05 ± 0.16-0.05 ± 0.17
M9 (n=266, 276)-0.08 ± 0.17-0.07 ± 0.16
M12 (n=259, 263)-0.09 ± 0.17-0.07 ± 0.16
M15 (n=247, 250)-0.12 ± 0.18-0.09 ± 0.17
M18 (n=237, 236)-0.12 ± 0.18-0.10 ± 0.18
M21 (n=232, 233)-0.13 ± 0.18-0.11 ± 0.18
M24 (n=223, 226)-0.15 ± 0.19-0.13 ± 0.18
Follow-up (FU) M1 (n=249, 221)-0.14 ± 0.18-0.14 ± 0.19
FU M3 (n=248, 231)-0.13 ± 0.21-0.14 ± 0.20
FU M6 (n=242, 220)-0.12 ± 0.20-0.15 ± 0.18
Extension (Ext) M1 (n=161, 163)-0.16 ± 0.20-0.16 ± 0.20
Ext M3 (n=157, 158)-0.19 ± 0.21-0.16 ± 0.19
Ext M6 (n=148, 159)-0.20 ± 0.21-0.17 ± 0.20
Ext M9 (n=144, 157)-0.19 ± 0.21-0.16 ± 0.21
Ext M12 (n=144, 157)-0.20 ± 0.21-0.18 ± 0.22
Ext M15 (n=141, 145)-0.22 ± 0.23-0.21 ± 0.20
Ext M18 (n=135, 139)-0.22 ± 0.23-0.21 ± 0.22
Ext M21 (n=132, 143)-0.23 ± 0.24-0.21 ± 0.21
Ext M24 (n=125, 131)-0.24 ± 0.24-0.23 ± 0.22
Ext M27 (n=124, 125)-0.25 ± 0.23-0.24 ± 0.22
Ext M30 (n=125, 126)-0.24 ± 0.22-0.23 ± 0.23
Ext M33 (n=98, 113)-0.24 ± 0.24-0.24 ± 0.22
Ext M36 (n=54, 60)-0.25 ± 0.18-0.28 ± 0.17
Ext M36 [LOCF] (n=171, 169)-0.24 ± 0.24-0.24 ± 0.21
Ext FU M3 (n=119, 115)-0.24 ± 0.21-0.25 ± 0.20
Statistical analysis
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.045 · 90% CI -0.064 to -0.026Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.003 · 90% CI -0.025 to 0.020Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.010 · 90% CI -0.033 to 0.013Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.020 · 90% CI -0.044 to 0.004Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.023 · 90% CI -0.048 to 0.003Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.023 · 90% CI -0.050 to 0.004Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.020 · 90% CI -0.047 to 0.007Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.026 · 90% CI -0.054 to 0.002Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.007 · 90% CI -0.021 to 0.034Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.014 · 90% CI -0.016 to 0.044Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.027 · 90% CI -0.002 to 0.055Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.004 · 90% CI -0.040 to 0.032Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.033 · 90% CI -0.070 to 0.004Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.039 · 90% CI -0.077 to -0.002Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.036 · 90% CI -0.075 to 0.003Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.018 · 90% CI -0.058 to 0.022Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.007 · 90% CI -0.034 to 0.048Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.011 · 90% CI -0.055 to 0.033Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.015 · 90% CI -0.058 to 0.029Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.015 · 90% CI -0.061 to 0.030Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.000 · 90% CI -0.044 to 0.043Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.005 · 90% CI -0.051 to 0.040Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.008 · 90% CI -0.042 to 0.058Adjusted Primary Analysis Model includes terms of treatment, baseline pulmonary function tests (PFTs), center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.024 · 90% CI -0.030 to 0.077Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.003 · 90% CI -0.042 to 0.035Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height. Ext M36 (LOCF) based on data in the extension phase only.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.019 · 90% CI -0.023 to 0.062Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
PrimaryAnnual Rate of Change in FEV1

Annual rate of change in FEV1 calculated as slope over time \[visit\] for forced expiratory volume in 1 second measured as liters per year (L/yr).

Time frame:
Week -2 through extension follow up Month 3 or end of study
Reported as:
Mean · L/yr

No measurements were reported for this outcome.

PrimarySummary of ≥ 15 % Decliners in FEV1

Number of subjects with a post-baseline FEV1 decrease of ≥ 15 % \[(baseline observed value - visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrrent illness, a repeat FEV1 was performed.

Time frame:
Month 3 through extension follow up Month 3
Reported as:
Number · participants
Summary of ≥ 15 % Decliners in FEV1
participantsInhaled Insulin (Exubera®)Subcutaneous Insulin
M3 (n=290, 291)22
M6 (n=281, 280)34
M9 (n=266, 276)75
M12 (n=259, 263)74
M15 (n=247, 250)136
M18 (n=237, 236)108
M21 (n=232, 233)128
M24 (n=223, 226)1413
FU M1 (n=249, 221)117
FU M3 (n=248, 231)1615
FU M6 (n=242, 220)1311
Ext M1 (n=161, 163)126
Ext M3 (n=157, 158)125
Ext M6 (n=148, 159)148
Ext M9 (n=144, 157)1110
Ext M12 (n=144, 157)1913
Ext M15 (n=141, 145)1511
Ext M18 (n=135, 139)1718
Ext M21 (n=132, 143)2211
Ext M24 (n=125, 131)2216
Ext M27 (n=124, 125)1814
Ext M30 (n=125, 126)2018
Ext M33 (n=98, 113)1012
Ext M36 (n=54, 60)56
Ext FU M3 (n=119, 115)1419
PrimaryAnnual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco)

Annual rate of change in DLco calculated as slope over time (visit) measured as milliliters per minute per millimeters of mercury per year (ml/min/mmHg/yr).

Time frame:
Week -2 through extension follow up Month 3 or end of study
Reported as:
Mean · ml/min/mmHg/yr

No measurements were reported for this outcome.

SecondaryForced Vital Capacity (FVC)

Forced Vital Capacity (FVC) measured in liters (L).

Time frame:
Week -3 through extension follow up Month 3 or end of study
Reported as:
Mean · L

No measurements were reported for this outcome.

SecondaryTotal Lung Capacity (TLC)

Total Lung Capacity measured in liters (L).

Time frame:
Baseline through extension follow up Month 3
Reported as:
Mean · L

No measurements were reported for this outcome.

SecondaryChange From Baseline in Glycosylated Hemoglobin (HbA1c)

Change from baseline: mean of (value of observed HbA1c \[%\] at treatment observation minus baseline value).

Time frame:
Baseline through extension follow up Month 3
Reported as:
Mean · percent
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
percentInhaled Insulin (Exubera®)Subcutaneous Insulin
Baseline (n=315, 303)7.66 ± 1.127.77 ± 1.12
Week 6 (W6) (n=291, 280)-0.64 ± 0.67-0.60 ± 0.70
M3 (n=296, 291)-0.80 ± 0.86-0.73 ± 0.89
M6 (n=284, 287)-0.67 ± 0.94-0.68 ± 1.00
M9 (n=270, 280)-0.56 ± 0.98-0.61 ± 0.93
M12 (n=261, 263)-0.45 ± 0.94-0.58 ± 1.00
M15(n=252, 258)-0.43 ± 1.00-0.51 ± 1.00
M18(n=244, 241)-0.42 ± 1.02-0.53 ± 1.06
M21 (n=236, 238)-0.43 ± 1.04-0.52 ± 1.02
M24 (n=226, 234)-0.35 ± 1.09-0.48 ± 1.13
FU M3 (n=225, 226)-0.41 ± 1.04-0.44 ± 1.06
FU M6 (n=230, 230)-0.27 ± 1.12-0.31 ± 1.06
Ext M1 (n=167, 162)-0.41 ± 1.16-0.40 ± 1.05
Ext M3 (n=164, 162)-0.33 ± 1.19-0.42 ± 1.05
Ext M6 (n=157, 163)-0.26 ± 1.11-0.40 ± 1.10
Ext M9 (n=152, 157)-0.11 ± 1.15-0.26 ± 1.13
Ext M12 (n=150, 157)-0.08 ± 1.19-0.17 ± 1.16
Ext M15(n=146, 151)-0.17 ± 1.30-0.25 ± 1.15
Ext M18 (n=145, 145)-0.20 ± 1.19-0.29 ± 1.17
Ext M21(n=137, 147)-0.13 ± 1.16-0.20 ± 1.20
Ext M24 (n=131, 137)-0.18 ± 1.21-0.23 ± 1.11
Ext M27(n=129, 132)-0.18 ± 1.13-0.28 ± 1.20
Ext M30 (n=129, 129)-0.20 ± 1.19-0.30 ± 1.19
Ext M33(n=104, 116)8.54 ± 88.44-0.18 ± 1.17
Ext M36 (n=55, 64)-0.20 ± 1.15-0.30 ± 1.18
Ext FU M3 (n=117, 116)-0.11 ± 1.40-0.17 ± 1.28
Statistical analysis
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.119 · 90% CI -0.215 to -0.023Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.023 · 90% CI -0.133 to 0.087Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.010 · 90% CI -0.104 to 0.124Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.091 · 90% CI -0.033 to 0.214Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.052 · 90% CI -0.081 to 0.185Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.090 · 90% CI -0.054 to 0.234Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.068 · 90% CI -0.073 to 0.208Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.100 · 90% CI -0.058 to 0.257Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.006 · 90% CI -0.143 to 0.154Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.036 · 90% CI -0.119 to 0.190Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.019 · 90% CI -0.200 to 0.161Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.081 · 90% CI -0.101 to 0.263Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.141 · 90% CI -0.038 to 0.320Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.150 · 90% CI -0.041 to 0.342Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.104 · 90% CI -0.090 to 0.298Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.074 · 90% CI -0.132 to 0.279Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.087 · 90% CI -0.111 to 0.284Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.064 · 90% CI -0.141 to 0.270Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.047 · 90% CI -0.156 to 0.249Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.067 · 90% CI -0.138 to 0.272Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.046 · 90% CI -0.171 to 0.264Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 9.824 · 90% CI -3.920 to 23.569Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.011 · 90% CI -0.316 to 0.337Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.024 · 90% CI -0.245 to 0.292Adjusted Primary Analysis Model includes terms of treatment, baseline HbA1c, and center.
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline: mean of (value of observed FPG \[milligrams per deciliter (mg/dL)\] at treatment observation minus baseline value).

Time frame:
Baseline through extension follow up Month 3
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG)
mg/dLInhaled Insulin (Exubera®)Subcutaneous Insulin
Baseline (n=315, 303)158.13 ± 42.71154.53 ± 41.51
W6 (n=282, 276)-23.36 ± 51.69-12.55 ± 50.46
M3 (n=294, 290)-26.38 ± 52.72-12.77 ± 54.93
M6 (n=281, 285)-25.21 ± 53.48-9.05 ± 68.42
M9 (n=267, 279)-26.68 ± 54.95-10.41 ± 56.42
M12 (n=260, 263)-20.55 ± 59.68-7.60 ± 60.03
M15(n=253, 255)-21.37 ± 54.53-8.82 ± 55.57
M18(n=242, 238)-24.52 ± 54.50-7.69 ± 58.47
M21(n=232, 237)-25.95 ± 53.06-13.14 ± 54.66
M24 (n=226, 232)-24.02 ± 54.45-8.91 ± 65.24
FU M3 (n=5, 4)-22.60 ± 44.65-4.08 ± 32.08
FU M6 (n=161, 156)-2.85 ± 66.18-1.56 ± 71.72
Ext M1 (n=165, 162)-17.91 ± 60.96-7.34 ± 60.98
Ext M3 (n=162, 159)-18.16 ± 66.59-9.29 ± 62.50
Ext M6 (n=152, 161)-15.65 ± 67.18-4.34 ± 61.96
Ext M9 (n=149, 155)-13.99 ± 61.68-6.06 ± 60.86
Ext M12 (n=148, 155)-12.53 ± 72.25-4.98 ± 62.92
Ext M15(n=143, 143)-6.88 ± 68.85-4.23 ± 65.21
Ext M18 (n=136, 138)-17.23 ± 65.97-10.32 ± 63.11
Ext M21(n=132, 144)-12.86 ± 63.98-6.53 ± 64.09
Ext M24 (n=129, 136)-14.45 ± 61.65-3.47 ± 68.57
Ext M27 (n=128, 129)-21.68 ± 58.35-3.76 ± 63.31
Ext M30 (n=127, 130)-11.80 ± 62.82-6.40 ± 61.47
Ext M33(n=103, 115)-16.26 ± 63.44-7.35 ± 66.21
Ext M36 (n=55, 64)-28.61 ± 65.99-13.35 ± 53.97
Ext FU M3 (n=115, 118)-2.87 ± 81.191.88 ± 64.94
Statistical analysis
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -12.39 · 90% CI -19.07 to -5.710Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -14.21 · 90% CI -22.11 to -6.312Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -10.96 · 90% CI -19.07 to -2.852Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -12.56 · 90% CI -20.89 to -4.232Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -16.83 · 90% CI -80.69 to 47.019Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 2.578 · 90% CI -9.257 to 14.412Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -9.460 · 90% CI -19.37 to 0.450Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -9.481 · 90% CI -20.11 to 1.153Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -10.76 · 90% CI -21.95 to 0.438Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -6.827 · 90% CI -16.98 to 3.328Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -7.287 · 90% CI -19.15 to 4.579Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.848 · 90% CI -13.76 to 10.066Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -9.022 · 90% CI -20.83 to 2.790Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -7.078 · 90% CI -18.99 to 4.834Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -12.53 · 90% CI -24.63 to -0.429Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -19.07 · 90% CI -30.45 to -7.685Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -3.220 · 90% CI -15.15 to 8.705Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -8.490 · 90% CI -21.09 to 4.107Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -21.88 · 90% CI -36.66 to -7.105Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -4.673 · 90% CI -19.16 to 9.812Adjusted Primary Analysis Model includes terms of treatment, baseline fasting plasma glucose, and center.
SecondaryChange From Baseline in Body Weight

Change from baseline: mean of (value of observed body weight \[kilograms (kg)\] at treatment observation minus baseline value).

Time frame:
Baseline through extension follow up Month 3
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgInhaled Insulin (Exubera®)Subcutaneous Insulin
Baseline (n=314, 302)87.18 ± 14.7588.31 ± 15.50
W4 (n=280, 270)0.63 ± 2.110.83 ± 1.86
W8 (n=289, 281)1.07 ± 2.411.00 ± 2.31
M3 (n=288, 290)1.08 ± 2.751.13 ± 2.55
W18(n=280, 285)1.33 ± 3.131.76 ± 3.03
M6 (n=276, 277)1.15 ± 3.591.89 ± 3.53
M9 (n=269, 274)1.50 ± 3.952.15 ± 3.90
M12 (n=259, 264)1.75 ± 4.292.37 ± 4.34
M15(n=247, 249)1.88 ± 4.332.62 ± 4.49
M18(n=237, 235)1.79 ± 4.532.93 ± 4.85
M21(n=232, 232)1.99 ± 4.563.04 ± 5.04
M24 (n=223, 226)2.04 ± 4.863.36 ± 5.16
FU M3 (n=249, 231)2.32 ± 5.253.63 ± 5.34
FU M6 (n=243, 218)2.38 ± 5.344.09 ± 7.70
Ext M1 (n=161, 162)2.87 ± 5.483.75 ± 5.58
Ext M3 (n=157, 157)2.83 ± 4.784.14 ± 5.69
Ext M6 (n=148, 159)3.15 ± 5.704.01 ± 6.07
Ext M9 (n=144, 156)2.95 ± 5.953.89 ± 5.87
Ext M12 (n=144, 156)2.96 ± 6.004.19 ± 6.12
Ext M15 (n=142, 145)3.12 ± 5.914.54 ± 6.26
Ext M18 (n=135, 139)3.33 ± 9.204.46 ± 6.12
Ext M21(n=132, 143)2.79 ± 6.905.01 ± 8.37
Ext M24 (n=126, 131)2.94 ± 6.984.57 ± 6.37
Ext M27(n=125, 125)2.99 ± 6.945.58 ± 9.62
Ext M30 (n=125, 126)3.39 ± 6.434.78 ± 6.96
Ext M33(n=99, 113)2.77 ± 6.335.22 ± 7.21
Ext M36 (n=54, 60)2.48 ± 6.615.28 ± 7.09
Ext FU M3 (n=119, 115)2.74 ± 6.904.44 ± 6.87
Statistical analysis
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.059 · 90% CI -0.416 to 0.299Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.735 · 90% CI -1.224 to -0.246Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.642 · 90% CI -1.251 to -0.032Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.355 · 90% CI -2.120 to -0.589Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.303 · 90% CI -2.086 to -0.520Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.557 · 90% CI -2.539 to -0.575Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.904 · 90% CI -1.898 to 0.090Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.280 · 90% CI -2.225 to -0.334Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.834 · 90% CI -1.909 to 0.241Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.001 · 90% CI -2.080 to 0.078Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.316 · 90% CI -2.431 to -0.200Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.512 · 90% CI -2.661 to -0.363Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.313 · 90% CI -2.824 to 0.198Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -2.399 · 90% CI -3.891 to -0.907Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.566 · 90% CI -2.867 to -0.265Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -2.720 · 90% CI -4.439 to -1.001Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.401 · 90% CI -2.755 to -0.047Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -2.281 · 90% CI -3.781 to -0.782Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -2.766 · 90% CI -4.932 to -0.599Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -1.637 · 90% CI -3.120 to -0.153Adjusted Primary Analysis Model includes terms of treatment, baseline weight, and center.
SecondaryTotal Daily Long-acting Insulin Dose (Unadjusted for Body Weight)

Total daily long-acting insulin dose unadjusted for body weight. Long-acting (units) insulin for inhaled insulin and subcutaneous treatment groups included NPH insulin, Ultralente®, and insulin glargine.

Time frame:
Month 3 through extension Month 36
Reported as:
Mean · units
Total Daily Long-acting Insulin Dose (Unadjusted for Body Weight)
unitsInhaled Insulin (Exubera®)Subcutaneous Insulin
M3 (n=301, 298)44.10 ± 25.6047.98 ± 25.06
M6 (n=289, 291)44.03 ± 26.2747.31 ± 25.47
M9 (n=275, 284)43.64 ± 26.1748.11 ± 26.02
M12 (n=266, 270)44.62 ± 27.4348.01 ± 26.02
M15 (n=258, 260)45.02 ± 27.7648.37 ± 26.48
M18 (n=243, 242)46.07 ± 27.7748.93 ± 27.60
M21 (n=240, 240)46.67 ± 29.0649.84 ± 28.73
M24 (n=229, 237)46.62 ± 28.5550.34 ± 29.31
Ext M1 (n=167, 164)45.29 ± 28.0051.29 ± 28.45
Ext M3 (n=165, 162)45.76 ± 28.6151.62 ± 28.71
Ext M6 (n=159, 164)45.89 ± 28.6152.18 ± 28.85
Ext M9 (n=156, 158)46.51 ± 29.3452.32 ± 28.89
Ext M12 (n=151, 158)46.52 ± 29.8451.72 ± 29.06
Ext M15 (n=148, 149)46.39 ± 30.1252.92 ± 29.83
Ext M18 (n=145, 145)46.31 ± 31.1752.37 ± 29.78
Ext M21 (n=137, 148)46.49 ± 31.1752.68 ± 29.40
Ext M24 (n=131, 137)47.21 ± 32.4252.18 ± 30.33
Ext M27 (n=132, 133)48.13 ± 32.7652.42 ± 29.87
Ext M30 (n=131, 130)48.13 ± 33.4153.22 ± 29.85
Ext M33 (n=104, 116)48.38 ± 32.4751.93 ± 30.65
Ext M36 (n=56, 65)46.42 ± 31.9153.47 ± 28.96
SecondaryTotal Daily Long-acting Insulin (Adjusted for Body Weight)

Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting (units) insulin for inhaled insulin and subcutaneous treatment groups included NPH insulin, Ultralente®, and insulin glargine.

Time frame:
Month 3 through extension Month 36
Reported as:
Mean · units/kg
Total Daily Long-acting Insulin (Adjusted for Body Weight)
units/kgInhaled Insulin (Exubera®)Subcutaneous Insulin
M3 (n=301, 298)0.51 ± 0.290.54 ± 0.27
M6 (n=289, 291)0.50 ± 0.290.54 ± 0.28
M9 (n=275, 284)0.50 ± 0.290.55 ± 0.29
M12 (n=266, 270)0.51 ± 0.300.55 ± 0.29
M15 (n=258, 260)0.52 ± 0.310.56 ± 0.30
M18 (n=243, 242)0.53 ± 0.310.57 ± 0.31
M21 (n=240, 240)0.53 ± 0.320.57 ± 0.32
M24 (n=229, 237)0.54 ± 0.320.58 ± 0.32
Ext M1 (n=167, 164)0.53 ± 0.330.59 ± 0.31
Ext M3 (n=165, 162)0.53 ± 0.340.59 ± 0.31
Ext M6 (n=159, 164)0.54 ± 0.340.60 ± 0.31
Ext M9 (n=156, 158)0.54 ± 0.350.60 ± 0.31
Ext M12 (n=151, 158)0.54 ± 0.360.60 ± 0.32
Ext M15 (n=148, 149)0.54 ± 0.360.61 ± 0.32
Ext M18 (n=145, 145)0.54 ± 0.370.61 ± 0.32
Ext M21 (n=137, 148)0.54 ± 0.370.61 ± 0.32
Ext M24 (n=131, 137)0.55 ± 0.390.61 ± 0.34
Ext M27 (n=132, 133)0.56 ± 0.390.61 ± 0.33
Ext M30 (n=131, 130)0.56 ± 0.410.62 ± 0.33
Ext M33 (n=104, 116)0.56 ± 0.370.61 ± 0.34
Ext M36 (n=56, 65)0.53 ± 0.370.61 ± 0.31
SecondaryTotal Daily Short-acting Insulin Dose (Unadjusted for Body Weight)

Total daily dose of short-acting insulin unadjusted for body weight. Short-acting insulin (milligrams \[mg\]) for the inhaled insulin treatment group was inhaled insulin; short-acting insulin (units) for the subcutaneous insulin treatment group included insulin lispro, insulin aspart, and regular insulin.

Time frame:
Month 3 through extension Month 36
Reported as:
Mean · mg, units
Total Daily Short-acting Insulin Dose (Unadjusted for Body Weight)
mg, unitsInhaled Insulin (Exubera®) (mg)Subcutaneous Insulin (Units)
M3 (n=302, 299)12.66 ± 6.8031.15 ± 18.75
M6 (n=290, 292)13.18 ± 6.9031.73 ± 19.08
M9 (n=275, 285)13.57 ± 7.5731.58 ± 18.89
M12 (n=266, 270)14.40 ± 7.9031.94 ± 19.29
M15 (n=258, 261)14.70 ± 8.0631.88 ± 19.37
M18 (n=245, 242)14.91 ± 8.4132.79 ± 20.70
M21 (n=240, 242)15.09 ± 8.5533.18 ± 20.92
M24 (n=229, 238)15.43 ± 8.6534.04 ± 21.84
Ext M1 (n=167, 164)13.89 ± 8.4734.52 ± 24.52
Ext M3 (n=165, 163)14.62 ± 9.1835.29 ± 23.19
Ext M6 (n=159, 165)14.62 ± 9.1635.43 ± 24.80
Ext M9 (n=156, 161)14.82 ± 9.1035.68 ± 24.72
Ext M12 (n=151, 160)15.42 ± 9.8136.56 ± 26.34
Ext M15 (n=148, 151)15.48 ± 9.9036.27 ± 25.51
Ext M18 (n=145, 146)15.57 ± 9.9337.37 ± 26.29
Ext M21 (n=138, 149)15.94 ± 10.4136.80 ± 27.09
Ext M24 (n=131, 138)15.46 ± 9.7038.51 ± 29.06
Ext M27 (n=132, 134)16.25 ± 10.3038.54 ± 28.13
Ext M30 (n=131, 131)16.56 ± 10.6339.01 ± 28.66
Ext M33 (n=105, 117)16.51 ± 10.4340.33 ± 30.81
Ext M36 (n=56, 66)17.25 ± 11.3042.34 ± 28.72
SecondaryTotal Daily Short-acting Insulin Dose (Adjusted for Body Weight)

Total daily dose of short-acting insulin adjusted for body weight. Short-acting insulin (mg) for the inhaled insulin treatment group was inhaled insulin (mg divided by kg); short-acting insulin (units) for the subcutaneous insulin treatment group included insulin lispro, insulin aspart, and regular insulin (units divided by kg).

Time frame:
Month 3 through extension Month 36
Reported as:
Mean · mg/kg, units/kg
Total Daily Short-acting Insulin Dose (Adjusted for Body Weight)
mg/kg, units/kgInhaled Insulin (Exubera®) (mg)Subcutaneous Insulin (Units)
M3 (n=302, 299)0.15 ± 0.070.36 ± 0.22
M6 (n=290, 292)0.15 ± 0.080.36 ± 0.22
M9 (n=275, 285)0.16 ± 0.080.36 ± 0.22
M12 (n=266, 270)0.17 ± 0.090.37 ± 0.23
M15 (n=258, 261)0.17 ± 0.090.37 ± 0.24
M18 (n=245, 242)0.17 ± 0.090.38 ± 0.25
M21 (n=240, 242)0.17 ± 0.090.39 ± 0.26
M24 (n=229, 238)0.18 ± 0.100.40 ± 0.27
Ext M1 (n=167, 164)0.16 ± 0.090.40 ± 0.30
Ext M3 (n=165, 163)0.17 ± 0.100.41 ± 0.26
Ext M6 (n=159, 165)0.17 ± 0.100.41 ± 0.30
Ext M9 (n=156, 161)0.17 ± 0.100.42 ± 0.30
Ext M12 (n=151, 160)0.18 ± 0.110.43 ± 0.32
Ext M15 (n=148, 151)0.18 ± 0.110.42 ± 0.31
Ext M18 (n=145, 146)0.18 ± 0.110.44 ± 0.32
Ext M21 (n=138, 149)0.18 ± 0.110.43 ± 0.33
Ext M24 (n=131, 138)0.18 ± 0.100.45 ± 0.35
Ext M27 (n=132, 134)0.19 ± 0.110.45 ± 0.34
Ext M30 (n=131, 131)0.19 ± 0.120.46 ± 0.34
Ext M33 (n=105, 117)0.19 ± 0.110.47 ± 0.36
Ext M36 (n=56, 66)0.19 ± 0.120.48 ± 0.31
SecondaryLipid Panel: Total Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, and Triglycerides

Lipid values for total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides measured as milligrams per deciliter (mg/dL).

Time frame:
Week -4 through Month 24
Reported as:
Mean · mg/dL

No measurements were reported for this outcome.

PrimaryChange From Baseline in Carbon Monoxide Diffusion Capacity (DLco)

Change from baseline: mean of (value of observed DLco \[milliliters per minute per millimeters of mercury (ml/min/mmHg)\] at treatment observation minus baseline value).

Time frame:
Baseline through extension follow up Month 3
Reported as:
Mean · ml/min/mmHg
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)
ml/min/mmHgInhaled Insulin (Exubera®)Subcutaneous Insulin
Baseline (n=308, 303)24.13 ± 5.5423.97 ± 5.72
M3 (n=289, 290)-0.57 ± 1.60-0.32 ± 1.62
M6 (n=278, 280)-0.56 ± 1.62-0.44 ± 1.73
M9 (n=266, 272)-0.67 ± 1.78-0.72 ± 1.77
M12 (n=258, 263)-0.72 ± 1.86-0.41 ± 1.87
M15 (n=246, 248)-0.81 ± 1.83-0.56 ± 1.96
M18 (n=237, 232)-0.86 ± 1.95-0.65 ± 1.92
M21 (n=231, 231)-0.89 ± 1.98-0.67 ± 1.92
M24 (n=221, 223)-0.74 ± 2.10-0.81 ± 2.06
FU M1 (n=247, 220)-0.46 ± 2.05-1.02 ± 2.01
FU M3 (n=247, 231)-0.58 ± 2.07-0.90 ± 2.15
FU M6 (n=241, 219)-0.64 ± 2.15-0.95 ± 2.11
Ext M1 (n=159, 161)-1.01 ± 2.08-1.09 ± 2.15
Ext M3 (n=157, 157)-1.07 ± 2.10-1.16 ± 2.45
Ext M6 (n=148, 157)-1.48 ± 1.87-1.26 ± 2.38
Ext M9 (n=143, 155)-1.15 ± 2.31-1.36 ± 2.54
Ext M12 (n=141, 155)-1.49 ± 2.22-1.59 ± 2.38
Ext M15 (n=141, 142)-1.49 ± 2.25-1.46 ± 2.41
Ext M18 (n=132, 138)-1.54 ± 2.25-1.63 ± 2.21
Ext M21 (n=129, 142)-1.33 ± 2.45-1.64 ± 2.45
Ext M24 (n=124, 130)-1.39 ± 2.27-1.46 ± 2.43
Ext M27 (n=123, 124)-1.35 ± 2.48-1.44 ± 2.41
Ext M30 (n=124, 125)-1.75 ± 2.13-1.62 ± 2.55
Ext M33 (n=98, 113)-1.47 ± 2.05-1.61 ± 2.25
Ext M36 (n=52, 60)-1.22 ± 2.16-1.87 ± 2.23
Ext M36 [LOCF] (n=171, 169)-1.39 ± 2.31-1.77 ± 2.46
Ext FU M3 (n=118, 114)-1.12 ± 2.15-1.69 ± 2.56
Statistical analysis
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.251 · 90% CI -0.466 to -0.037Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.095 · 90% CI -0.323 to 0.134Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.084 · 90% CI -0.158 to 0.325Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.266 · 90% CI -0.524 to -0.009Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.181 · 90% CI -0.453 to 0.091Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.141 · 90% CI -0.427 to 0.145Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.155 · 90% CI -0.445 to 0.134Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.119 · 90% CI -0.193 to 0.431Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.617 · 90% CI 0.322 to 0.911Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.354 · 90% CI 0.051 to 0.657Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.318 · 90% CI 0.011 to 0.626Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.136 · 90% CI -0.227 to 0.500Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.098 · 90% CI -0.289 to 0.485Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.202 · 90% CI -0.576 to 0.172Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.245 · 90% CI -0.180 to 0.669Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.126 · 90% CI -0.284 to 0.535Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.023 · 90% CI -0.395 to 0.441Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.146 · 90% CI -0.262 to 0.554Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.321 · 90% CI -0.138 to 0.780Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.043 · 90% CI -0.419 to 0.506Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.190 · 90% CI -0.279 to 0.659Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): -0.117 · 90% CI -0.579 to 0.346Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.262 · 90% CI -0.189 to 0.714Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.267 · 90% CI -0.370 to 0.904Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.399 · 90% CI -0.003 to 0.802Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height. Ext M36 (LOCF) based on data in the extension phase only.
  • Inhaled Insulin (Exubera®) vs Subcutaneous Insulin · Mean difference (final values): 0.619 · 90% CI 0.137 to 1.102Adjusted Primary Analysis Model includes terms of treatment, baseline PFTs, center, age, sex, and height.
PrimarySummary of ≥ 20 % Decliners in DLco

Number of subjects with a post-baseline DLco decrease of ≥ 20 % \[(baseline observed value - visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrrent illness, a repeat DLco was performed.

Time frame:
Month 3 through extension follow up Month 3
Reported as:
Number · participants
Summary of ≥ 20 % Decliners in DLco
participantsInhaled Insulin (Exubera®)Subcutaneous Insulin
M3 (n=289, 290)02
M6 (n=278, 280)12
M9 (n=266, 272)03
M12 (n=258, 263)43
M15 (n=246, 248)12
M18(n=237, 232)25
M21 (n=231, 231)03
M24 (n=221, 223)45
FU M1 (n=247, 220)24
FU M3 (n=247, 231)36
FU M6 (n=241, 219)55
Ext M1 (n=159, 161)33
Ext M3 (n=157, 157)38
Ext M6 (n=148, 157)46
Ext M9 (n=143, 155)47
Ext M12 (n=141, 155)89
Ext M15(n=141, 142)46
Ext M18 (n=132, 138)67
Ext M21(n=129, 142)48
Ext M24 (n=124, 130)57
Ext M27(n=123, 124)78
Ext M30 (n=124, 125)711
Ext M33(n=98, 113)14
Ext M36 (n=52, 60)23
Ext FU M3 (n=118, 114)610
SecondaryHypoglycemic Event Rates

Hypoglycemic event rate; hypoglycemic event identified by characteristic symptoms of hypoglycemia with no blood glucose (BG) check with prompt resolution with food intake, SC glucagon, or intravenous (IV) glucose; characteristic symptoms with BG of 59 mg/dL (3.2 mmol/L) or less with or without symptoms. Crude event rate = total events divided by subject months (elapsed number of months a subject was in the study at each time interval).

Time frame:
Month 1 through extension Month 36
Reported as:
Number · event rate (events/subject months)
Hypoglycemic Event Rates
event rate (events/subject months)Inhaled Insulin (Exubera®)Subcutaneous Insulin
M1 (n=315, 303)1.631.80
M2 (n=307, 302)1.401.60
M3 (n=297, 298)1.221.65
M4 (n=289, 295)1.101.64
M5 (n=284, 293)0.951.28
M6 (n=283, 290)0.981.09
M7 (n=280, 289)0.801.12
M8 (n=276, 288)0.820.94
M9 (n=275, 287)0.710.86
M10 (n=273, 285)0.720.93
M11 (n=267, 274)0.680.79
M12 (n=264, 274)0.720.94
M13 (n=263, 269)0.710.82
M14 (n=260, 265)0.620.87
M15 (n=256, 265)0.640.78
M16 (n=254, 261)0.680.97
M17 (n=252, 257)0.530.82
M18 (n=246, 253)0.610.95
M19 (n=245, 252)0.590.78
M20 (n=242, 249)0.620.73
M21 (n=241, 246)0.570.65
M22 (n=236, 244)0.440.72
M23 (n=236, 241)0.410.82
M24 (n=229, 232)0.450.66
Ext M1 (n=172, 169)1.161.16
Ext M2 (n=171, 169)1.101.33
Ext M3 (n=169, 169)1.021.12
Ext M4 (n=167, 169)0.871.44
Ext M5 (n=165, 168)0.911.18
Ext M6 (n=162, 167)0.871.20
Ext M7 (n=161, 167)1.101.41
Ext M8 (n=158, 164)0.821.34
Ext M9 (n=158, 164)0.561.25
Ext M10 (n=156, 164)0.991.11
Ext M11 (n=153, 164)0.700.92
Ext M12 (n=152, 162)1.261.25
Ext M13 (n=152, 160)1.071.14
Ext M14 (n=151, 159)0.951.01
Ext M15 (n=149, 156)0.861.25
Ext M16 (n=149, 156)0.991.23
Ext M17 (n=148, 154)1.201.01
Ext M18 (n=146, 154)1.081.05
Ext M19 (n=143, 152)1.251.21
Ext M20 (n=142, 152)1.201.08
Ext M21 (n=141, 151)0.781.15
Ext M22 (n=141, 149)0.791.08
Ext M23 (n=139, 149)0.821.06
Ext M24 (n=138, 147)0.881.11
Ext M25 (n=137, 146)0.731.22
Ext M26 (n=137, 145)0.681.25
Ext M27 (n=137, 141)0.621.04
Ext M28 (n=135, 137)0.680.87
Ext M29 (n=135, 137)0.810.91
Ext M30 (n=133, 137)0.640.87
Ext M31 (n=124, 133)0.671.32
Ext M32 (n=117, 125)0.820.81
Ext M33 (n=100, 117)0.550.89
Ext M34 (n=84, 90)0.640.57
Ext M35 (n=66, 78)0.630.80
Ext M36 (n=51, 60)0.720.47
Overall comparative (n=315, 303)0.951.19
Overall extension (n=172, 169)0.891.10
SecondarySevere Hypoglycemic Event Rates

Severe hypoglycemic event rate; all 3 criteria were met: subject unable to treat self, exhibited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty awakening, suspected seizure, loss of consciousness); BG measurement ≤49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, SC glucagon, or IV glucose. Crude event rate: total events divided by subject months multiplied by 100 (\[total events/subject months\]\*100). Subjects months: elapsed number of months subject was in study in each time interval.

Time frame:
Month 1 through extension Month 36
Reported as:
Number · event rate (events/subject months*100)
Severe Hypoglycemic Event Rates
event rate (events/subject months*100)Inhaled Insulin (Exubera®)Subcutaneous Insulin
M1 (n=315, 303)0.980.67
M2 (n=307, 302)0.340.34
M3 (n=297, 298)0.690.34
M4 (n=289, 295)0.351.38
M5 (n=284, 293)0.361.74
M6 (n=283, 290)0.722.10
M7 (n=280, 289)0.000.70
M8 (n=276, 288)0.370.70
M9 (n=275, 287)0.740.35
M10 (n=273, 285)0.000.36
M11 (n=267, 274)0.380.37
M12 (n=264, 274)0.760.37
M13 (n=263, 269)0.770.76
M14 (n=260, 265)0.780.38
M15 (n=256, 265)0.790.77
M16 (n=254, 261)0.000.00
M17 (n=252, 257)0.000.40
M18 (n=246, 253)0.000.40
M19 (n=245, 252)0.410.00
M20 (n=242, 249)0.420.00
M21 (n=241, 246)0.000.00
M22 (n=236, 244)0.000.00
M23 (n=236, 241)0.000.85
M24 (n=229, 232)0.000.00
Ext M1 (n=172, 1690.950.93
Ext M2 (n=171, 169)0.001.87
Ext M3 (n=169, 169)1.920.94
Ext M4 (n=167, 169)1.920.00
Ext M5 (n=165, 168)0.000.00
Ext M6 (n=162, 167)0.000.94
Ext M7 (n=161, 167)0.001.90
Ext M8 (n=158, 164)0.000.00
Ext M9 (n=158, 164)0.002.86
Ext M10 (n=156, 164)0.003.81
Ext M11 (n=153, 164)0.003.86
Ext M12 (n=152, 162)0.983.91
Ext M13 (n=152, 160)0.000.98
Ext M14 (n=151, 159)0.001.96
Ext M15 (n=149, 156)1.000.00
Ext M16 (n=149, 156)1.001.96
Ext M17 (n=148, 154)1.000.99
Ext M18 (n=146, 154)1.010.00
Ext M19 (n=143, 152)1.030.99
Ext M20 (n=142, 152)4.160.99
Ext M21 (n=141, 151)0.000.00
Ext M22 (n=141, 149)0.001.00
Ext M23 (n=139, 149)0.000.00
Ext M24 (n=138, 147)1.062.02
Ext M25 (n=137, 146)0.001.01
Ext M26 (n=137, 145)0.000.00
Ext M27 (n=137, 141)1.070.00
Ext M28 (n=135, 137)0.000.00
Ext M29 (n=135, 137)0.001.06
Ext M30 (n=133, 137)0.000.00
Ext M31 (n=124, 133)0.001.15
Ext M32 (n=117, 125)0.003.58
Ext M33 (n=100, 117)0.000.00
Ext M34 (n=84, 90)0.001.89
Ext M35 (n=66, 78)0.000.00
Ext M36 (n=51, 60)0.000.82
Overall comparative (n=315, 303)0.450.65
Overall extension (n=172, 169)0.501.17
SecondaryCough Questionnaire

Clinician administered 6 question instrument to measure cough frequency (night, day), severity, timing in relation to short-acting insulin dosing, severity related to insulin dosing (SC or inhaled), and productivity of cough; range 0 (indicates no symptoms) to 4 (indicates severe symptoms). Questionnaire administered at Week 0 then if and only if, cough is identified as an adverse event not explained by a concomitant condition, such as an upper respiratory tract infection.

Time frame:
Week 0 and if indicated through extension follow up Month 3
Reported as:
Number · scores on scale

No measurements were reported for this outcome.

SecondaryBaseline Dyspnea Index (BDI)

Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI score range 0 (very severe impairment) to 4 (no impairment) scaled to a BDI focal score (0-12). Lower score indicates greater impairment.

Time frame:
Week -1
Reported as:
Number · scores on scale

No measurements were reported for this outcome.

SecondaryTransition Dyspnea Index (TDI)

Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI score range -3 (major deterioration) to +3 (major improvement); sum of all domains yields the TDI focal score (-9 to +9); lower score indicates greater deterioration. Compared to previous scoring to determine deterioration or improvement.

Time frame:
Week 4 through extension follow up Month 3 or end of study
Reported as:
Number · scores on scale

No measurements were reported for this outcome.

SecondaryHigh Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Within Normal Limits

Number of subjects with Yes or No responses (within normal limits at specified time points = Yes or not within normal limits at specified time points = No) at observation when HRCT of thorax was within normal limits at baseline.

Time frame:
Baseline, M12, M24, Ext M6, Ext M18, Ext M36
Reported as:
Number · participants
High Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Within Normal Limits
participantsInhaled Insulin (Exubera®)Subcutaneous Insulin
M12 = Yes6764
M12 = No412
M24 = Yes3851
M24 = No810
Ext M6 = Yes3237
Ext M6 = No88
Ext M18 = Yes2833
Ext M18 = No86
Ext M36 = Yes2227
Ext M36 = No64
SecondaryHigh Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Not Within Normal Limits

Number of subjects with Yes or No responses (within normal limits at specified time points = Yes or not within normal limits at specified time points = No) at observation when HRCT of thorax was not within normal limits at baseline. "No" response at observation further categorized as no significant change (NSC), more abnormal (\> Abn), or less abnormal (\< Abn).

Time frame:
Baseline, M12, M24, Ext M6, Ext M18, Ext M36
Reported as:
Number · participants
High Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Not Within Normal Limits
participantsInhaled Insulin (Exubera®)Subcutaneous Insulin
M12 = Yes65
M12 = No2016
M12 = No (NSC)1911
M12 = No (> Abn)02
M12 = No (< Abn)13
M24 = Yes46
M24 = No179
M24 = No (NSC)178
M24 = No (> Abn)01
M24 = No (< Abn)00
Ext M6 = Yes33
Ext M6 = No169
Ext M6 = No (NSC)158
Ext M6 = No (> Abn)11
Ext M6 = No (< Abn)00
Ext M18 = Yes32
Ext M18 = No147
Ext M18 = No (NSC)127
Ext M18 = No (> Abn)10
Ext M18 = No (< Abn)10
Ext M24 = Yes52
Ext M24 = No98
Ext M24 = No (NSC)88
Ext M24 = No (> Abn)10
Ext M24 = No (< Abn)00
SecondaryInsulin Antibodies

Observed values for insulin antibodies measured as micro units per milliliter (microU/mL).

Time frame:
Baseline through extension Month 36
Reported as:
Median · microU/mL
Insulin Antibodies
microU/mLInhaled Insulin (Exubera®)Subcutaneous Insulin
Baseline (n=312, 300)1.05 (1.05 to 328.00)1.05 (1.05 to 1077.00)
W3 (n=270, 264)1.05 (1.05 to 948.00)1.05 (1.05 to 552.00)
W6 (n=289, 282)4.40 (1.05 to 7296.00)1.05 (1.05 to 2123.00)
M3 (n=293, 289)12.00 (1.05 to 2748.00)1.05 (1.05 to 4016.00)
W18 (n=275, 280)18.00 (1.05 to 1051.00)1.05 (1.05 to 3648.00)
M6 (n=276, 279)20.00 (1.05 to 1424.00)1.05 (1.05 to 3380.00)
M9 (n=267, 277)22.00 (1.05 to 1776.00)1.05 (1.05 to 3412.00)
M12 (n=263, 263)19.00 (1.05 to 1464.00)1.05 (1.05 to 1200.00)
M15 (n=252, 253)20.00 (1.05 to 1760.00)1.05 (1.05 to 1780.00)
M18 (n=241, 239)20.00 (1.05 to 1680.00)1.05 (1.05 to 1820.00)
M21 (n=234, 233)19.00 (1.05 to 1331.00)1.05 (1.05 to 2230.00)
M24 (n=226, 233)20.00 (1.05 to 1330.00)1.05 (1.05 to 1965.00)
FU M1 (n=247, 226)14.00 (1.05 to 974.00)1.05 (1.05 to 2135.00)
FU M3 (n=249, 229)8.50 (1.05 to 686.00)1.05 (1.05 to 1070.00)
FU M6 (n=250, 227)6.55 (1.05 to 641.00)1.05 (1.05 to 1480.00)
Ext M1 (n=165, 160)13.00 (1.05 to 894.00)1.05 (1.05 to 1270.00)
Ext M3 (n=159, 158)15.00 (1.05 to 755.00)1.05 (1.05 to 765.00)
Ext M6 (n=157, 156)12.00 (1.05 to 1200.00)1.05 (1.05 to 612.00)
Ext M9 (n=150, 157)11.50 (1.05 to 1855.00)1.05 (1.05 to 905.00)
Ext M12 (n=148, 154)13.00 (1.05 to 1535.00)1.05 (1.05 to 683.00)
Ext M15 (n=144, 147)10.50 (1.05 to 1860.00)1.05 (1.05 to 770.00)
Ext M18 (n=140, 144)13.00 (1.05 to 1080.00)1.05 (1.05 to 455.00)
Ext M21 (n=136, 145)12.00 (1.05 to 801.00)1.05 (1.05 to 620.00)
Ext M24 (n=130, 135)10.50 (1.05 to 831.00)1.05 (1.05 to 696.00)
Ext M27 (n=129, 131)12.00 (1.05 to 885.00)2.50 (1.05 to 208.00)
Ext M30 (n=125, 127)8.40 (1.05 to 510.00)1.05 (1.05 to 429.00)
Ext M33 (n=103, 114)9.20 (1.05 to 700.00)1.05 (1.05 to 637.00)
Ext M36 (n=56, 63)5.75 (1.05 to 168.00)1.05 (1.05 to 321.00)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Insulin (Exubera®)—76/316 (24.1%)308/316 (97.5%)
Subcutaneous Insulin—76/311 (24.4%)301/311 (96.8%)
Most frequent serious events
Showing 10 of 160
Most frequent serious events
EventInhaled Insulin (Exubera®)Subcutaneous Insulin
HypoglycaemiaMetabolism and nutrition disorders4/31612/311
CellulitisInfections and infestations7/3165/311
Myocardial infarctionCardiac disorders4/3165/311
Chest painGeneral disorders2/3165/311
Coronary artery diseaseCardiac disorders5/3163/311
Abdominal painGastrointestinal disorders0/3164/311
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/3161/311
Angina unstableCardiac disorders1/3163/311
PneumoniaInfections and infestations2/3163/311
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/3163/311
Most frequent other events
Showing 10 of 43
Most frequent other events
EventInhaled Insulin (Exubera®)Subcutaneous Insulin
HypoglycaemiaMetabolism and nutrition disorders245/316247/311
CoughRespiratory, thoracic and mediastinal disorders142/31670/311
Upper respiratory tract infectionInfections and infestations104/316101/311
NasopharyngitisInfections and infestations83/31694/311
InfluenzaInfections and infestations63/31676/311
HypertensionVascular disorders52/31662/311
Back painMusculoskeletal and connective tissue disorders43/31652/311
ArthralgiaMusculoskeletal and connective tissue disorders51/31643/311
TremorNervous system disorders37/31650/311
DiarrhoeaGastrointestinal disorders49/31627/311

Baseline characteristics

Age, Customized
Age, Customized(participants)Inhaled Insulin (Exubera®)Subcutaneous InsulinTotal
Between 26 and 35 years279
Between 36 and 45 years364985
Between 46 and 55 years10093193
Between 56 and 65 years117101218
Between 66 and 75 years6161122
Age Continuous
Age Continuous(years)Inhaled Insulin (Exubera®)Subcutaneous InsulinTotal
Mean56.7 ± 9.255.5 ± 9.956.1 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled Insulin (Exubera®)Subcutaneous InsulinTotal
Female111118229
Male205193398
08

Study locations

92 sites
  • Pfizer Investigational Site
    Phoenix, Arizona 85016, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85715, United States
  • Pfizer Investigational Site
    Fresno, California 93720, United States
  • Pfizer Investigational Site
    Greenbrae, California 94904, United States
  • Pfizer Investigational Site
    Los Angeles, California 90073, United States
  • Pfizer Investigational Site
    Sacramento, California 95816, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    San Diego, California 92108, United States
  • Pfizer Investigational Site
    San Luis Obispo, California 93401, United States
  • Pfizer Investigational Site
    Tustin, California 92780, United States
  • Pfizer Investigational Site
    Walnut Creek, California 94598, United States
  • Pfizer Investigational Site
    Denver, Colorado 80209, United States
  • Pfizer Investigational Site
    Hamden, Connecticut 06518, United States
  • Pfizer Investigational Site
    Madison, Connecticut 06443, United States
  • Pfizer Investigational Site
    New Britain, Connecticut 06050, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Chiefland, Florida 32626, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33761, United States
  • Pfizer Investigational Site
    Fort Myers, Florida 33901, United States
  • Pfizer Investigational Site
    Hollywood, Florida 33021, United States
  • Pfizer Investigational Site
    Miami, Florida 33156, United States
  • Pfizer Investigational Site
    Ocala, Florida 34471, United States
  • Pfizer Investigational Site
    Palm Harbor, Florida 34684, United States
  • Pfizer Investigational Site
    Tallahassee, Florida 32308, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33401, United States
  • Pfizer Investigational Site
    Honolulu, Hawaii 96813, United States
  • Pfizer Investigational Site
    Honolulu, Hawaii 96814, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60602, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60607, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60610, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62704, United States
  • Pfizer Investigational Site
    Wilmette, Illinois 60091, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70112, United States
  • Pfizer Investigational Site
    Bethesda, Maryland 20817, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48106, United States
  • Pfizer Investigational Site
    Bloomfield Hills, Michigan 48302, United States
  • Pfizer Investigational Site
    Plymouth, Michigan 48170, United States
  • Pfizer Investigational Site
    Royal Oak, Michigan 48073, United States
  • Pfizer Investigational Site
    Southfield, Michigan 48034, United States
  • Pfizer Investigational Site
    Chesterfield, Missouri 63017, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Butte, Montana 59701, United States
  • Pfizer Investigational Site
    Lincoln, Nebraska 68521, United States
  • Pfizer Investigational Site
    Henderson, Nevada 89014, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87108, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87109, United States
  • Pfizer Investigational Site
    Mineola, New York 11501, United States
  • Pfizer Investigational Site
    New Hyde Park, New York 11042, United States
  • Pfizer Investigational Site
    Rochester, New York 14609, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27713, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Mansfield, Ohio 44903, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74104, United States
  • Pfizer Investigational Site
    Warwick, Rhode Island 02886, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77701, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77706, United States
  • Pfizer Investigational Site
    Corpus Christi, Texas 78411, United States
  • Pfizer Investigational Site
    Corpus Christi, Texas 78412, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
  • Pfizer Investigational Site
    Houston, Texas 77079, United States
  • Pfizer Investigational Site
    Irving, Texas 75061, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Burlington, Vermont 05401, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23225, United States
  • Pfizer Investigational Site
    Renton, Washington 98055, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Pfizer Investigational Site
    Porto Alegre, RS 90035-170, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01244-030, Brazil
  • Pfizer Investigational Site
    Calgary, Alberta T2T 5C7, Canada
  • Pfizer Investigational Site
    Calgary, Alberta T3B 0M3, Canada
  • Pfizer Investigational Site
    Red Deer, Alberta T4N 6V7, Canada
  • Pfizer Investigational Site
    Victoria, British Columbia V8R 1J8, Canada
  • Pfizer Investigational Site
    Winnepeg, Manitoba R3A 1R9, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 4V2, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1H 1A2, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M4N-3M5, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5G 1X5, Canada
  • Pfizer Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3A 1A1, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Pfizer Investigational Site
    Aguas Buenas, 00703, Puerto Rico
  • Pfizer Investigational Site
    Anasco, 00610, Puerto Rico
  • Pfizer Investigational Site
    Cabo Rojo, 00623, Puerto Rico
  • Pfizer Investigational Site
    San Juan, 00909, Puerto Rico
  • Pfizer Investigational Site
    San Juan, 00921, Puerto Rico
09

References and documents

Publications

  • Rosenstock J, Cefalu WT, Hollander PA, Klioze SS, Reis J, Duggan WT. Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial. Diabetes Technol Ther. 2009 Nov;11(11):697-705. doi: 10.1089/dia.2009.0062. PubMed 19905885 ↗
  • Rosenstock J, Cefalu WT, Hollander PA, Belanger A, Eliaschewitz FG, Gross JL, Klioze SS, St Aubin LB, Foyt H, Ogawa M, Duggan WT. Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care. 2008 Sep;31(9):1723-8. doi: 10.2337/dc08-0159. Epub 2008 Jun 5. PubMed 18535196 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2005
First posted
Aug 29, 2005
Start
Jun 2002
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jan 18, 2010
Last update
Feb 18, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00136916
Lead sponsor
Pfizer
First posted
Aug 29, 2005
Start date
Jun 2002
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jan 18, 2010
Last update
Feb 18, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion